These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23254686)

  • 21. Serum-autoantibodies for discovery of prostate cancer specific biomarkers.
    Massoner P; Lueking A; Goehler H; Höpfner A; Kowald A; Kugler KG; Amersdorfer P; Horninger W; Bartsch G; Schulz-Knappe P; Klocker H
    Prostate; 2012 Mar; 72(4):427-36. PubMed ID: 22012634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
    Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
    Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoantibodies directed against the ribosomal P proteins are not only directed against a common epitope of the P0, P1 and P2 proteins.
    Fabien N; Moreira A; Lavergne JP; Desbos A; Surgey P; Alves de Olivera C; Gonzalo P; Venot A; Bienvenu J; Perrier H; Reboud JP; Monier JC
    J Autoimmun; 1999 Aug; 13(1):103-10. PubMed ID: 10441174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
    Gulley JL; Arlen PM; Bastian A; Morin S; Marte J; Beetham P; Tsang KY; Yokokawa J; Hodge JW; Ménard C; Camphausen K; Coleman CN; Sullivan F; Steinberg SM; Schlom J; Dahut W
    Clin Cancer Res; 2005 May; 11(9):3353-62. PubMed ID: 15867235
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.
    Sanda MG; Smith DC; Charles LG; Hwang C; Pienta KJ; Schlom J; Milenic D; Panicali D; Montie JE
    Urology; 1999 Feb; 53(2):260-6. PubMed ID: 9933036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens.
    Hemstreet GP; Rossi GR; Pisarev VM; Enke CA; Helfner L; Hauke RJ; Tennant L; Ramsey WJ; Vahanian NN; Link CJ
    J Immunother; 2013 Jan; 36(1):57-65. PubMed ID: 23211622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard treatments induce antigen-specific immune responses in prostate cancer.
    Nesslinger NJ; Sahota RA; Stone B; Johnson K; Chima N; King C; Rasmussen D; Bishop D; Rennie PS; Gleave M; Blood P; Pai H; Ludgate C; Nelson BH
    Clin Cancer Res; 2007 Mar; 13(5):1493-502. PubMed ID: 17332294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses to all ErbB family receptors detectable in serum of cancer patients.
    Bei R; Masuelli L; Moriconi E; Visco V; Moretti A; Kraus MH; Muraro R
    Oncogene; 1999 Feb; 18(6):1267-75. PubMed ID: 10022808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
    Bradford TJ; Wang X; Chinnaiyan AM
    Urol Oncol; 2006; 24(3):237-42. PubMed ID: 16678056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ribosomal P protein P0 as a candidate for the target antigen of anti-endothelial cell antibodies in mixed connective tissue disease.
    Naniwa T; Sugiura Y; Banno S; Yoshinouchi T; Matsumoto Y; Ueda R
    Clin Exp Rheumatol; 2007; 25(4):593-8. PubMed ID: 17888216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
    O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
    Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination of cytotoxic T lymphocyte-directed peptides elicited and spread humoral and Th1-type immune responses to prostate-specific antigen protein in a prostate cancer patient.
    Harada M; Matsueda S; Yao A; Noguchi M; Itoh K
    J Immunother; 2005; 28(4):368-75. PubMed ID: 16000955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer.
    D'Amico AV; Schultz D; Loffredo M; Dugal R; Hurwitz M; Kaplan I; Beard CJ; Renshaw AA; Kantoff PW
    JAMA; 2000 Sep; 284(10):1280-3. PubMed ID: 10979115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibodies against small heat-shock proteins in Alzheimer's disease as a part of natural human immune repertoire or activation of humoral response?
    Papuć E; Krupski W; Kurys-Denis E; Rejdak K
    J Neural Transm (Vienna); 2016 Apr; 123(4):455-61. PubMed ID: 26566902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
    DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
    Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of antibodies against the native ribosomal P protein complex and recombinant P0, P1, and P2 proteins in the diagnosis of Chinese patients with systemic lupus erythematosus.
    Li J; Shen Y; He J; Jia R; Wang X; Chen X; Wang D; Han L; Zhu L; Chi X; Saschenbrecker S; Dähnrich C; Stöcker W; Schlumberger W; Li ZG
    J Clin Lab Anal; 2013 Mar; 27(2):87-95. PubMed ID: 23400861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
    Jeong JU; Nam TK; Song JY; Yoon MS; Ahn SJ; Chung WK; Cho IJ; Kim YH; Cho SH; Jung SI; Kang TW; Kwon DD
    PLoS One; 2021; 16(3):e0248461. PubMed ID: 33711055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.